A clinical trial run across two geographies usually means three vendors, two standards, and no single owner — and every handoff between adviser, CRO, and local agent taxes the timeline and dilutes accountability. That is the offshore CRO friction tax. The way to avoid it is an in-house CRO India model with a DCGI-registered operation, where the team that scopes the study is the team that runs it, to one written standard on both continents.
Sponsors who have been burned by offshore work rarely complain about capability. They complain about the seams — the places where one vendor hands to the next and time, clarity, and accountability leak out.
Where the tax is levied
Picture a typical India engagement assembled from parts. A consultant sets the regulatory strategy. A CRO runs clinical operations. A local agent handles the in-country regulatory filing. A separate lab does the testing. On paper, each is competent. In practice, the program pays a tax at every boundary between them:
- The regulatory filing is built by someone who never saw the global protocol, so it carries inconsistencies the Subject Expert Committee catches.
- The operational plan rediscovers decisions the strategy already made, because the people executing were not the people who set it.
- When a query lands, no single party can answer it without consulting the others, and the calendar runs while they coordinate.
- Quality is held to whichever standard each vendor defaults to, not one written standard the sponsor can point to in an inspection.
None of these is a failure of skill. They are failures of structure. And they add up to months.
Why “cheaper” can cost more
The irony is that the multi-vendor model is often chosen to save money, and it is exactly the model that quietly spends it — in delayed activation, in rework after a query, in a readout that slips past the runway. For a clinical-stage company, time against cash is the binding constraint, and friction is a tax paid in the one currency you cannot raise more of.
The in-house alternative
The structural fix is to collapse the seams. An in-house, DCGI-registered operation runs the strategy, the regulatory filing, the clinical operations, and the data under one roof, with one engagement lead who owns delivery from protocol to database lock. Because the team executing is the team that built the plan, the operational design reflects the regulatory and CMC decisions instead of rediscovering them. There is no relay, no re-explaining your program to a new face each month, and one written standard held across both geographies.
Speed, in this model, is not bought by cutting controls. It is earned by removing the gaps where months normally leak away.
What to ask a prospective partner
Two questions surface the friction fast. First: “Who, by name, owns my program end to end?” If the answer is a committee of vendors, you will pay the tax. Second: “Is the regulatory filing built by the same team that runs the operations?” If not, expect the inconsistencies the SEC will find.
Frequently asked questions
Q: What is the offshore-friction tax? A: The time and accountability lost at every handoff when a trial is run across multiple vendors — adviser, CRO, local agent, lab — each operating to its own standard, with no single owner.
Q: How does an in-house CRO reduce it? A: By keeping strategy, regulatory, operations, and data under one accountable team and one documentation standard, so nothing waits in the gap between vendors and the plan never drifts from the execution.
Q: Does in-house mean slower or more expensive? A: The opposite, usually. Friction — not the work itself — is where multi-vendor programs lose time and money. Removing the handoffs is what compresses the timeline.
Running an India program across too many vendors? See the in-house model. → eteraflexconnects.com/services/clinical-operations/
